RÉSUMÉ DIGEST

ACT 391 (HB 319) **2015 Regular Session** **Simon**

With respect to interchangeable biological products, new law defines "biological product" and amends the definition of "equivalent drug product".

New law requires the dispensing pharmacist or his designee, no later than five business days following the dispensing of a biological product, to communicate to the prescriber the specific product provided to the patient, including the name of the product and the manufacturer. Further authorizes the required communication to be done by any means.

New law provides no communication is required if any of the following conditions exist:

(1) There is no interchangeable or therapeutical equivalent biological product approved by the United States Food and Drug Administration for the product prescribed.

(2) The prescription is a refill not changed from the product dispensed on the prior filling of the prescription.

(3) The prescriber indicates dispense as written.

Nothing in new law creates a cause of action against the prescriber and the dispensing pharmacist or his designee for a communication as required pursuant to new law.

Effective August 1, 2015.

(Amends R.S. 37:1164(16); Adds R.S. 37:1164(58) and 1226.1)